$DMAC News

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

DiaMedica Therapeutics Announces 75% Enrollment In Its Phase 2/3 ReMEDy2 trial of DM199 In Patients With Acute Ischemic Stroke

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans

DiaMedica Therapeutics Q1 Earnings Call Highlights

DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript

DiaMedica Therapeutics (NASDAQ:DMAC) Posts Wider Q1 Loss but Clinical Catalysts Fuel Stock Resilience

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Q1 EPS $(0.19), Inline

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference

DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...

DiaMedica Therapeutics Inc. Q4 2025 Earnings Call Summary

DiaMedica Therapeutics Q4 Earnings Call Highlights

DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Q4 EPS $(0.17) Beats $(0.18) Estimate

DiaMedica Therapeutics Q4 EPS $(0.17) Beats $(0.18) Estimate

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026